NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer

Trends in Biochemical Sciences

Volumn 34, Issue 4, 2009, Pages 176-188

  Hayes, John D ^a   McMahon, Michael ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 BIOTINAMIDO 4 (4' [MALEIMIDOETHYL CYCLOHEXANE]CARBOXAMIDO)BUTANE; 1 CHLORO 2,4 DINITROBENZENE; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 4 HYDROXYNONENAL; ALLYL SULFIDE; AMIDE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIOXIDANT ARE; BIOTINYLATED IODOACETAMIDE; BUTYLATED HYDROXYANISOLE; CARBOPLATIN; CIRCUMIN; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE 21 MESILATE; DITHIOLETHIONE; ELECTROPHILE; ETHOXYQUIN; ETOPOSIDE; FLUOROURACIL; IODOACETAMIDE; ISOTHIOCYANIC ACID DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; OXIDIZING AGENT; SULFORAPHANE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANTIOXIDANT RESPONSIVE ELEMENT; CELL ACTIVATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CYTOPLASM; DETOXIFICATION; DRUG MECHANISM; ENHANCER REGION; EPIGENETICS; GENE ACTIVATION; GENE IDENTIFICATION; GENE INDUCTION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; HUMAN; KNOCKOUT MOUSE; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR GENETICS; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REDOX STRESS; REGULATORY MECHANISM; REVIEW; SOMATIC CELL; SOMATIC MUTATION; TUMOR CELL;

ADAPTATION, BIOLOGICAL; ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NF-E2-RELATED FACTOR 2;

EID: 63549121490     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2008.12.008     Document Type: Review

References (128)

1. Halliwell B., and Gutteridge J.M.C. Free Radicals in Biology and Medicine. 4th edn (2007), Oxford University Press
2. Klaassen C.D. Toxicology: the Basic Science of Poisons. 7th edn (2008), McGraw-Hill
3. Motohashi H., and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10 (2004) 549-557
4. Rushmore T.H., et al. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266 (1991) 11632-11639
5. Nioi P., et al. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem. J. 374 (2003) 337-348
6. McMahon M., et al. The Cap'n' Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 61 (2001) 3299-3307
7. Kim Y.C., et al. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J. Biol. Chem. 276 (2001) 18399-18406
8. Osborne S.A., and Tonissen K.F. Genomic organisation and alternative splicing of mouse and human thioredoxin reductase 1 genes. BMC Genomics 2 (2001) 10
9. Chanas S.A., et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J. 365 (2002) 405-416
10. Thimmulappa R.K., et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62 (2002) 5196-5203
11. Kwak M.K., et al. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell. Biol. 22 (2002) 2883-2892
12. Sasaki H., et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277 (2002) 44765-44771
13. Pietsch E.C., et al. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J. Biol. Chem. 278 (2003) 2361-2369
14. Kwak M.K., et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278 (2003) 8135-8145
15. Rangasamy T., et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114 (2004) 1248-1259
16. Katsuoka F., et al. Nrf2 transcriptionally activates the mafG gene through an antioxidant response element. J. Biol. Chem. 280 (2005) 4483-4490
17. Cho H.Y., et al. Gene expression profiling of NRF2-mediated protection against oxidative injury. Free Radic. Biol. Med. 38 (2005) 325-343
18. Yeh C.T., and Yen G.C. Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis 26 (2005) 2138-2148
19. Okawa H., et al. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 339 (2006) 79-88
20. -/- mice. Cancer Lett. 243 (2006) 170-192
21. Maher J.M., et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46 (2007) 1597-1610
22. Reddy N.M., et al. Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection. Physiol. Genomics 32 (2007) 74-81
23. Osburn W.O., et al. Genetic or pharmacologic amplification of Nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol. Sci. 104 (2008) 218-227
24. Nioi P., and Hayes J.D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555 (2004) 149-171
25. Cho H.Y., et al. Linkage analysis of susceptibility to hyperoxia. Nrf2 is a candidate gene. Am. J. Respir. Cell Mol. Biol. 26 (2002) 42-51
26. Cho H.Y., et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 26 (2002) 175-182
27. Kensler T.W., et al. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 89-116
28. Aoki Y., et al. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol. 173 (2001) 154-160
29. Kwak M.K., et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat. Res. 480-481 (2001) 305-315
30. Ramos-Gomez M., et al. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24 (2003) 461-467
31. Aoki Y., et al. Enhanced spontaneous and benzo(a)pyrene-induced mutations in the lung of Nrf2-deficient gpt δ mice. Cancer Res. 67 (2007) 5643-5648
32. Kotlo K.U., et al. Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells. Oncogene 22 (2003) 797-806
33. Morito N., et al. Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 22 (2003) 9275-9281
34. Hayes J.D., et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans. 28 (2000) 33-41
35. Ramos-Gomez M., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3410-3415
36. Iida K., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 64 (2004) 6424-6431
37. Itoh K., et al. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol. 15 (1995) 4184-4193
38. Motohashi H., et al. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 294 (2002) 1-12
39. Itoh K., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13 (1999) 76-86
40. Nioi P., et al. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol. Cell. Biol. 25 (2005) 10895-10906
41. Katoh Y., et al. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6 (2001) 857-868
42. McMahon M., et al. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem. 279 (2004) 31556-31567
43. Adams J., et al. The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell Biol. 10 (2000) 17-24
44. Zipper L.M., and Mulcahy R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J. Biol. Chem. 277 (2002) 36544-36552
45. Li X., et al. Crystal structure of the Kelch domain of human Keap1. J. Biol. Chem. 279 (2004) 54750-54758
46. Dinkova-Kostova A.T., et al. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 44 (2005) 6889-6899
47. Stogios P.J., and Privé G.G. The BACK domain in BTB-kelch proteins. Trends Biochem. Sci. 29 (2004) 634-637
48. Snyder G.H., et al. Electrostatic influence of local cysteine environments on disulfide exchange kinetics. Biochemistry 20 (1981) 6509-6519
49. Zhang D.D., and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23 (2003) 8137-8151
50. Wakabayashi N., et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2040-2045
51. Kobayashi A., et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 26 (2006) 221-229
52. Nioi P., and Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 362 (2007) 816-821
53. Yamamoto T., et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol. Cell. Biol. 28 (2008) 2758-2770
54. Dinkova-Kostova A.T., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11908-11913
55. Levonen A.L., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378 (2004) 373-382
56. Hong F., et al. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem. 280 (2005) 31768-31775
57. Hong F., et al. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem. Res. Toxicol. 18 (2005) 1917-1926
58. Eggler A.L., et al. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10070-10075
59. Holland R., et al. Prospective type 1 and type 2 disulfides of Keap1 protein. Chem. Res. Toxicol. 21 (2008) 2051-2060
60. Wakabayashi N., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35 (2003) 238-245
61. Devling T.W., et al. Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7280-7285A
62. Gasper A.V., et al. Consuming broccoli does not induce genes associated with xenobiotic metabolism and cell cycle control in human gastric mucosa. J. Nutr. 137 (2007) 1718-1724
63. Kobayashi M., et al. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells 7 (2002) 807-820
64. Padmanabhan B., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 21 (2006) 689-700
65. Lo S.C., et al. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 25 (2006) 3605-3617
66. McMahon M., et al. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281 (2006) 24756-24768
67. Tong K.I., et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol. Cell. Biol. 27 (2007) 7511-7521
68. Strachan G.D., et al. Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like Ech-associated protein. Biochemistry 43 (2004) 12113-12122
69. Karapetian R.N., et al. Nuclear oncoprotein prothymosin α is a partner of Keap1: implications for expression of oxidative stress-protecting genes. Mol. Cell. Biol. 25 (2005) 1089-1099
70. Lo S.C., and Hannink M. PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. J. Biol. Chem. 281 (2006) 37893-37903
71. Lo S.C., and Hannink M. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. Exp. Cell Res. 314 (2008) 1789-1803
72. Kang M.I., et al. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2046-2051
73. Huang H.C., et al. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 277 (2002) 42769-42774
74. Yu R., et al. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem. 275 (2000) 2322-2327
75. Lee J.M., et al. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J. Biol. Chem. 276 (2001) 20011-20016
76. Kang K.W., et al. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol. Pharmacol. 62 (2002) 1001-1010
77. Keum Y.S., et al. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm. Res. 20 (2003) 1351-1356
78. Cullinan S.B., and Diehl J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J. Biol. Chem. 279 (2004) 20108-20117
79. Salazar M., et al. Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 281 (2006) 14841-14851
80. Xu C., et al. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol. Cancer Ther. 5 (2006) 1918-1926
81. Apopa P.L., et al. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J. Biochem. Mol. Toxicol. 22 (2008) 63-76
82. Nguyen T., et al. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J. Biol. Chem. 280 (2005) 32485-32492
83. Sun Z., et al. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol. 27 (2007) 6334-6349
84. Watai Y., et al. Subcellular localization and cytoplasmic complex status of endogenous Keap1. Genes Cells 12 (2007) 1163-1178
85. McMahon M., et al. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 278 (2003) 21592-21600
86. Kobayashi A., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24 (2004) 7130-7139
87. Cullinan S.B., et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24 (2004) 8477-8486
88. Zhang D.D., et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24 (2004) 10941-10953
89. Furukawa M., and Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 25 (2005) 162-171
90. Pintard L., et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 425 (2003) 311-316
91. Lo S.C., and Hannink M. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Mol. Cell. Biol. 26 (2006) 1235-1244
92. Petroski M.D., and Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6 (2005) 9-20
93. Zhang D.D., et al. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 280 (2005) 30091-30099
94. Rachakonda G., et al. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 21 (2008) 705-710
95. Clements C.M., et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15091-15096
96. Li W., et al. Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. J. Biol. Chem. 281 (2006) 27251-27263
97. Jain A.K., and Jaiswal A.K. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J. Biol. Chem. 281 (2006) 12132-12142
98. Miao W., et al. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem. 280 (2005) 20340-20348
99. Marzec J.M., et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 21 (2007) 2237-2246
100. 1. Biochem. J. 263 (1989) 393-402
101. 1. Pharmacol. Ther. 50 (1991) 443-472
102. Hayes J.D., and Wolf C.R. Molecular mechanisms of drug resistance. Biochem. J. 272 (1990) 281-295
103. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54 (1994) 4313-4320
104. McLellan L.I., and Wolf C.R. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist. Updat. 2 (1999) 153-164
105. Leslie E.M., et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
106. Ikeda H., et al. CCAAT enhancer-binding protein α suppresses the rat placental glutathione S-transferase gene in normal liver. J. Biol. Chem. 281 (2006) 6734-6741
107. Singh A., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3 (2006) e420
108. Ohta T., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68 (2008) 1303-1309
109. Shibata T., et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135 (2008) 1358-1368
110. Wang R., et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 373 (2008) 151-154
111. Shibata T., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13568-13573
112. Panani A.D., and Roussos C. Cytogenetic and molecular aspects of lung cancer. Cancer Lett. 239 (2006) 1-9
113. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
114. Arnér E.S., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000) 6102-6109
115. Reddy N.M., et al. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 27 (2008) 5821-5832
116. Singh A., et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68 (2008) 7975-7984
117. Ni M., and Lee A.S. ER chaperones in mammalian development and human diseases. FEBS Lett. 581 (2007) 3641-3651
118. Venugopal R., and Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14960-14965
119. Nguyen T., et al. Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J. Biol. Chem. 275 (2000) 15466-15473
120. Ikeda Y., et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2. J. Biol. Chem. 275 (2000) 33142-33150
121. Ansell P.J., et al. Repression of cancer protective genes by 17β-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor α. Mol. Cell. Endocrinol. 243 (2005) 27-34
122. Zhou W., et al. ERRβ: a potent inhibitor of Nrf2 transcriptional activity. Mol. Cell. Endocrinol. 278 (2007) 52-62
123. Wang X.J., et al. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor α. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19589-19594
124. Brown S.L., et al. Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-regulated stress pathway. Cancer Res. 68 (2008) 364-368
125. Liu G.H., et al. NF-κB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim. Biophys. Acta 1783 (2008) 713-727
126. Frohlich D.A., et al. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 27 (2008) 4353-4362
127. Ito N., et al. Carcinogenicity and modification of the carcinogenic response by BHA, BHT, and other antioxidants. Crit. Rev. Toxicol. 15 (1985) 109-150
128. Hayes J.D., and McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol. Cell 21 (2006) 732-734